Provided is a coloring composition containing a colorant, a resin, a polymerizable compound, a photopolymerization initiator, an ultraviolet absorber, and a solvent, in which the colorant contains an unsubstituted copper phthalocyanine pigment and a halogenated copper phthalocyanine pigment, a content of the unsubstituted copper phthalocyanine pigment in a total mass of the colorant is 10% by mass or more, and a content of the halogenated copper phthalocyanine pigment in the total mass of the colorant is 40% by mass or more.

A near-infrared absorbing composition includes: an organic dye; and a metal compound. The organic dye includes: at least one of a squarylium dye (A) or a cyanine dye (B) each having an absorption maximum in a range of 680 to 740 nm; and a cyanine dye (C) having an absorption maximum at 760 nm or higher. The metal compound includes at least a phosphonic acid and a copper ion, or a copper phosphonate complex formed from a phosphonic acid and a copper ion.

Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.

An optical member for use in a display device having a specific light emitting unit, which includes a specific light bending part and a light absorbing part having an absorption waveform selected from specific absorption waveforms A to D and having absorption waveform B: a specific absorption waveform in which two wavelengths that give an absorbance of half of an absorption maximum are present in a wavelength range larger than λ.sub.BMax (a maximum emission wavelength exhibited by blue emission of the display device) and smaller than λ.sub.GMax (a maximum emission wavelength exhibited by green emission of the display device) or C: a specific absorption waveform in which two wavelengths that give an absorbance of half of an absorption maximum are present in a wavelength range larger than λ.sub.GMax and smaller than λ.sub.RMax (a maximum emission wavelength exhibited by red emission of the display device).

Provided are any one of the following compounds and a fluorescently labeled biological substance having this compound.

##STR00001##

R.sup.1 to R.sup.27, L.sup.11, L.sup.12, and X.sup.+ represent a specific group, and at least one of R.sup.1 to R.sup.4 represents a substituted alkyl group.

In a case where at least one of R.sup.1 to R.sup.4 is an alkyl group having a carboxy group or a substituent capable of being bonded to a biological substance, at least one of R.sup.11 to R.sup.27 is an alkyl group or an aryl group, or at least one of R.sup.1 to R.sup.4, which does not correspond to the alkyl group having a carboxy group or an alkyl group having a substituent capable of being bonded to a biological substance, is an alkyl group having a sulfoalkyl group through a single bond or a linking group.

The total of n1 to n4 is an integer of 3 or more, and m=n1+n2+n3+n4−1 is satisfied.

At least one of R.sup.1 to R.sup.4, R.sup.13, L.sup.11 or L.sup.12 in Formula (1) and at least one of R.sup.1 to R.sup.4, R.sup.24, L.sup.11, or L.sup.12 in Formula (2) have a specific substituent.

Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density π-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R.sup.1, R.sup.2, R.sup.3 substituted phenyl where each of R.sup.1, R.sup.2, and R.sup.3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR.sup.4, N(R.sup.5).sub.2, or a combination thereof; each R.sup.4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R.sup.5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle. The devices include at least two dye-sensitized solar cells connected in series.

The present invention disclosed a squaraine dye of formula (I) and process for the preparation thereof. Further, the present invention disclosed to an electronic device comprising dye of formula (I).

Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a tinker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.

Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a linker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.

The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.